Press Room

Event

Connect in Pharma 2023

Start
Wednesday, June 14, 2023 - 00:00
End
Thursday, June 15, 2023 - 00:00
Location: Palexpo, Geneva
Connect in pharma 2023 | Hovione

Hovione presenting at the upcoming “Connect in Pharma” in Geneva.

 

Connect in Pharma drives innovation, business, and new partnerships in four key areas: Innovative packaging, drug delivery systems, CMO/CDMO, and filling & assembling processes, supporting pioneers in the pharma and biopharma industry. With conferences, workshops and curated networking “Connect in Pharma” offers a platform to drive innovation and solve challenges.

 

On June 14, José Luís Santos, Director of Technology Intensification will host a session on “The Role of a CDMO in Accelerating the Adoption of Continuous Tableting” and will join a group of experts during a panel discussion on the topic of “Continuous Manufacturing of solid dosage forms: state of the art and future advances”.

 

Session | The Role of a CDMO in Accelerating the Adoption of Continuous Tableting

Wednesday 14 June, 2:00 PM - 2:30 PM (Theatre 2)

 

The application of continuous tableting (CT) is steadily developing a foundation in the pharmaceutical industry. Large pharma organizations have been at the forefront of adoption due to their evolving development pipelines that justify the technological disruption. However, systemic application of CT requires more than individually owned installations and can only be achieved with the partnership of the health authorities, equipment vendors, and contract development and manufacturing organizations (CDMOs).

A CDMO role is particularly important for the adoption of emerging technologies such as CT, in that an equipment standard needs to be established where most of the industry can seamlessly integrate with their own development, manufacturing, and supply chains. The processes and knowledge of owning and operating the technology must be broad, yet robust, to assure that the benefits outweigh the perceived risks by a meaningful margin.

This talk will focus on the key areas that require attention for the adoption of CT by the industry, and how at Hovione we are setting ourselves up for successful deployment of the technology.

 

Panel Discussion | Continuous Manufacturing of solid dosage forms: state of the art and future advances

Wednesday 14 June, 3:30 PM - 4:00 PM (Theatre 2)

 

We look forward to seeing you in Geneva.

 

Find out today if Continuous Tableting is right for your product.

Connect with our experts and get to know more about the distinct set of features and advantages that allows going from development to manufacturing in record time with high quality and less variability.

The future is continuous.

 

Let’s discuss your project together.

schedule a meeting
https://go.hovione.com/l/47122/2014-08-06/9grc



 

 

 

Find more about Connect in Pharma.

 

Also in the Press Room

See All

Aim to accelerate drug development and production with new technologies. By: Charlie Sternberg Hovione, an international integrated pharmaceutical development and manufacturing organization, and Microinnova Engineering, a leader in continuous process intensification, have partnered to advance the development of multi-purpose, plug-and-play modular equipment for flow chemistry. The companies will work together to test Microinnova’s modular manufacturing equipment, which is designed to offer greater flexibility, easier scalability, enhanced efficiency, and sustainable practices in active ingredient production, in an industrial setting. Together, the companies aim to accelerate process development, facilitate a seamless transition from lab to large-scale manufacturing, and ultimately reduce the time to market for pharmaceutical customers. “This collaboration with Microinnova underscores Hovione’s commitment to innovation in pharmaceutical manufacturing, with flow chemistry playing an important role in our long-term drug substance strategy,” said Dr. Jean-Luc Herbeaux, CEO of Hovione. “This partnership will allow us to shape and validate emerging continuous manufacturing technologies, which can potentially accelerate drug development and production.” Dr. Dirk Kirschneck, Founder and Strategic Director at Microinnova, added, “This partnership reflects our shared vision to deliver modular manufacturing technologies that support pharmaceutical innovation and manufacturing excellence. We are proud to join forces with Hovione to showcase the capabilities of our next-generation modular equipment in a dynamic CDMO environment, demonstrating its versatility for multi-purpose manufacturing.”   Read the full article on ContractPharma.com  

Press Clipping
Contract Pharma, 24 September 2025

Hovione, Microinnova Partner to Test Modular Manufacturing Equipment

Sep 24, 2025

Hovione is a global contract development and manufacturing organization (CDMO) company founded in Portugal in 1959. With approximately 2,400 team members worldwide, the company provides comprehensive services for drug substances, drug intermediates, and drug products in countries around the world. Japan in particular plays a very important role in Hovione's global strategy, and in 2017 it established a Japanese subsidiary in Osaka. The company plans to actively invest in further strengthening its organization and recruiting personnel. With development labs strategically located in Lisbon, Portugal, and New Jersey, USA, Hovione consistently provides superior solutions tailored to complex pharmaceutical challenges. Hovione is recognized globally for its scientific excellence, technological innovation, and customer-centric and integrated approach. Leveraging cutting-edge capabilities in chemical synthesis, particle engineering, and formulation development, the company supports its partners throughout the entire pharmaceutical life cycle.   Read the full article in Japanese Read the article translated in English   Visit the Yakuji Nippo online      

Press Clipping
Yakuji Nippo Magazine, 2 July 2025

Solving Complex Pharmaceutical Challenges

Jul 10, 2025

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping
Pharmiweb.com, 25 June 2025

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025

Also in Events

See All